10 stories from 4 sources
Supporting Articles
Merck agreed to buy US medical tools maker Bio-Techne for $11.3bn, marking its biggest acquisition in more than a decade. The deal expands Merck’s life sciences tools footprint in a market driven by bioprocessing and lab demand.
6:16 AMFinancial TimesGermany has topped $120 billion in announced mergers and acquisitions as several long-anticipated transactions finally moved from talk to signed deals. The surge is putting the country on track for one of its busiest M-and-A years in decades, with industrial assets among the main drivers.
3:28 AMBloomberg MarketsAdobe is acquiring Topaz Labs, whose software enhances and upscales images and video. Adobe says it will integrate Topaz’s tools across its creative apps.
9:30 AMTechCrunchSummary
Merck agreed to buy US medical tools maker Bio-Techne for $11.3bn, marking its biggest acquisition in more than a decade. The deal expands Merck’s life sciences tools footprint in a market driven by bioprocessing and lab demand.
Why it matters
It signals renewed big-ticket consolidation in life sciences tools and could reset competitive dynamics and pricing across labs and biomanufacturing.
Summary
Germany has topped $120 billion in announced mergers and acquisitions as several long-anticipated transactions finally moved from talk to signed deals. The surge is putting the country on track for one of its busiest M-and-A years in decades, with industrial assets among the main drivers.
Why it matters
A sustained German M-and-A rebound signals confidence in pricing and capital access, and it can reset valuations and competitive dynamics across European industrials.
Summary
Adobe is acquiring Topaz Labs, whose software enhances and upscales images and video. Adobe says it will integrate Topaz’s tools across its creative apps.
Why it matters
The deal signals Adobe’s intent to consolidate high-demand AI enhancement capabilities inside Creative Cloud, reshaping the plug-in ecosystem and creator costs.
A curated list of other prominent stories from this day.
Elroy Air is in advanced talks to go public by merging with a SPAC in a transaction that would value the combined company at about $1bn enterprise value. The company is developing cargo drones aimed at moving freight that would otherwise go by delivery truck.
11:54 PMBloomberg MarketsSBI Holdings agreed to acquire Japanese crypto exchange Bitbank for about $289 million. The deal brings a major local trading venue under a large regulated financial group.
8:01 PMFinextraEasyJet is in talks with Castlelake after rejecting a £4.9 billion takeover offer from the US private credit group. The discussions suggest Castlelake is still pursuing a transaction despite the initial rebuff.
5:55 AMFinancial TimesH.B. Fuller agreed to buy Advanced Medical Solutions Group, a UK-listed maker of tissue-healing medical products, for £659 million. The deal moves H.B. Fuller deeper into medical adhesives and wound-care materials.
2:57 AMBloomberg MarketsH.B. Fuller is close to an agreement to acquire Advanced Medical Solutions Group in a transaction valuing AMS equity at about £628 million ($827 million). AMS makes tissue-healing and wound-care products.
1:50 AMBloomberg MarketsAri Emanuel is in advanced talks to buy UK theatre group ATG Entertainment in a deal valuing it at about £4.5bn. The potential acquisition would put a major portfolio of West End and Broadway venues under a Hollywood dealmaker’s control.
12:00 AMFinancial TimesBiopharma buyers are driving a wave of biotech M&A that increasingly targets early-stage drug assets, not just late-stage products that can quickly replace revenues lost to patent expiries. The deal mix suggests acquirers are paying up for platform potential and future pipelines rather than near-term earnings.
12:00 AMFinancial TimesSummary
Elroy Air is in advanced talks to go public by merging with a SPAC in a transaction that would value the combined company at about $1bn enterprise value. The company is developing cargo drones aimed at moving freight that would otherwise go by delivery truck.
Why it matters
A successful SPAC would reopen public financing for capital-intensive cargo drone bets and accelerate competitive pressure on last-mile and regional freight.
Summary
SBI Holdings agreed to acquire Japanese crypto exchange Bitbank for about $289 million. The deal brings a major local trading venue under a large regulated financial group.
Why it matters
The acquisition accelerates consolidation and regulation-led institutionalization of Japan's crypto exchange sector.
Summary
EasyJet is in talks with Castlelake after rejecting a £4.9 billion takeover offer from the US private credit group. The discussions suggest Castlelake is still pursuing a transaction despite the initial rebuff.
Why it matters
A credible private credit buyer staying at the table could reopen take-private playbooks for airlines and reshape how the sector gets financed.
Summary
H.B. Fuller agreed to buy Advanced Medical Solutions Group, a UK-listed maker of tissue-healing medical products, for £659 million. The deal moves H.B. Fuller deeper into medical adhesives and wound-care materials.
Why it matters
The acquisition signals continued consolidation in healthcare materials as industrial chemical companies chase steadier, premium-margin growth.
Summary
H.B. Fuller is close to an agreement to acquire Advanced Medical Solutions Group in a transaction valuing AMS equity at about £628 million ($827 million). AMS makes tissue-healing and wound-care products.
Why it matters
It is a read-through on strategic appetite and pricing in mid-market healthcare M&A, with implications for other UK-listed medtech targets and buyer behavior.
Summary
Ari Emanuel is in advanced talks to buy UK theatre group ATG Entertainment in a deal valuing it at about £4.5bn. The potential acquisition would put a major portfolio of West End and Broadway venues under a Hollywood dealmaker’s control.
Why it matters
Control of premier theatre real estate can reshape who gets stage access and who captures margins in live entertainment.
Summary
Biopharma buyers are driving a wave of biotech M&A that increasingly targets early-stage drug assets, not just late-stage products that can quickly replace revenues lost to patent expiries. The deal mix suggests acquirers are paying up for platform potential and future pipelines rather than near-term earnings.
Why it matters
If the boom is driven by pipeline construction rather than patent-gap patching, valuation, integration strategy, and failure risk will define returns over the next 3 to 7 years.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!